Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

June 13, 2007 08:00 ET

Ambrilia Targets a New Category of HIV Integrase Inhibitors

MONTREAL, QUEBEC--(Marketwire - June 13, 2007) - Ambrilia Biopharma (TSX:AMB) presented today preclinical data on its novel series of HIV integrase inhibitors, a high potential new anti-HIV therapy, during a poster session at the prestigious XVI International HIV Drug Resistance Workshop. The data showed their potential distinct mechanism of action, which may lead to a different resistance profile from known integrase inhibitors currently in clinical development by pharmaceutical companies.

As well, during the same conference, Merck & Co., Inc. presented an abstract on HIV Protease Inhibitor PPL-100 which Ambrilia co-authored along with Dr. Mark Wainberg of McGill University. Last October, the Company out-licensed PPL-100 and its related compounds to Merck.

"Integrase inhibitors emerge as one of the most promising new classes of drugs for the treatment of HIV/AIDS. These data suggesting that Ambrilia has potentially a new category of HIV integrase inhibitors underway are encouraging. Thus, development of these compounds is one of our priorities for the coming months and into next year", said Dr. Bonabes de Rouge, Ambrilia's Senior Executive Vice-President and Chief Scientific Officer. "As well, we are pleased to have collaborated with our partner Merck on the PPL-100 abstract, which presents new data on the structural basis for PPL-100's favorable resistance profile", he concluded.

These data will be highlighted by Ambrilia's Executive Committee during the Annual General Meeting to be held tomorrow, Thursday, June 14th, at the Maxwell-Cummings Auditorium of The Montreal Museum of Fine Arts, 1379 Sherbrooke Street W. The meeting will start at 10:30AM and will be followed by a session with the media at approximately 11:45AM.


Contact Information